iECURE
Stephen Squinto, Ph.D. is chief investment officer & managing partner at J.P. Morgan Life Sciences Private Capital. Previously an executive partner with OrbiMed, he brings more than 30 years of experience in the biotechnology company building and investing space. He was a co-founder of Alexion Pharmaceuticals, Inc. and served as its executive VP and chief global operations officer. Prior to 2013, he was Alexion’s global head of R&D. While at Alexion, he was responsible for the discovery, development and launch of several successful biotechnology products. From 1988 to 1992, he held various positions at Regeneron Pharmaceuticals, Inc. Prior to Regeneron, he held a joint academic position at both the Tulane University and LSU Medical Schools. Stephen is a recipient of numerous honors and awards from academic and professional organizations for his scientific work. He received his B.A. in chemistry and Ph.D. in biochemistry and biophysics from Loyola University of Chicago.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
iECURE
1 followers
iECURE is a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need. We believe our approach has the potential to replace and restore the function of a dysfunctional gene by knocking-in a healthy copy, regardless of mutation, to offer durable gene expression and long-term, potentially curative, therapeutic benefit. Our management team has extensive experience in executing global orphan drug and gene therapy clinical trials and successfully commercializing multiple products. We intend to leverage our team’s core strength in research and development strategy to identify what we believe to be the most suitable target and modality for our product candidates to address particular liver diseases. We are collaborating with the University of Pennsylvania’s Gene Therapy Program, or GTP, led by James M. Wilson, M.D., Ph.D., to utilize GTP’s world-class translational expertise and infrastructure, which has helped generate our initial pipeline of potential product candidates.